Supported by promising data generated during the option period, Coya has entered into an exclusive license for a next-generation EET platform to enable engineering of exosomes with potential to target ...
China Medical University Hospital (CMUH), under the leadership of Superintendent Dr. Cho Der-Yang, announced a major ...
- Alliance to explore the utility of engineered exosomes developed with Codiak’s engEx™ Platform to deliver gene therapy, gene editing and RNA technologies - - Two-year, global research and option ...
The exosome services offered by Creative Biolabs undergo new developments in exosome sampling, isolation, purification, and analysis services. SHIRLEY, NY, UNITED ...
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced that six preclinical data ...
OXFORD, England, Oct. 7, 2021 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, announces that it has, in close collaboration with one of its ...
HYDERABAD, India, Dec. 8, 2025 /PRNewswire/ -- According to Mordor Intelligence, the global exosomes market is valued at USD 0.71 billion in 2025 and is projected to surpass USD 2.21 billion by 2030, ...
Advancing Exosome Technology to Address Inflammatory Conditions in Women's Health SEOUL, EUNPYEONG, SOUTH KOREA, July 9, 2025 /EINPresswire.com/ -- ILIAS Biologics ...
The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune ...
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results